Want to see MMSI full AI Analyst Report?

Merit Medical Systems (MMSI) Earnings Dates, Call Summary & Reports

345 Followers

Earnings Data

Report Date

Jul 29, 2026

After Close (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

0.96

Last Year’s EPS

1.01

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 10 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:Apr 30, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call was largely positive: Merit beat revenue and earnings expectations in Q1, delivered the highest first-quarter operating margin in company history, generated stronger free cash flow, and closed strategic acquisitions (Viewpoint, BioLife, C2) that expand high-growth therapeutic markets. Near-term headwinds include a steep OEM decline in the quarter, tariff impacts and uncertainty, divestiture-related revenue drag, a recent Class I recall (managed as immaterial), and Q2 guidance reflecting some margin and EPS pressure. Management reiterated solid full-year guidance and confidence in organic and inorganic growth and emphasized disciplined cost/control efforts and platform alignment.

Company Guidance

Merit updated 2026 guidance calling for GAAP net revenue growth of 6.3%–7.8% y/y (constant currency 5.6%–7.0%, excluding an ~80 bps FX tailwind) with inorganic revenue of ~$17–20M (up from prior $13–15M) that includes Viewpoint Medical contributing $2–4M (acquired 4/1) and an assumed $7M of Rhapsody CIE U.S. sales; excluding inorganic, organic constant‑currency growth is guided at ~4.5%–6.0%, with foundational products expected to grow mid‑single digits and therapeutic products high‑single digits. Profitability guidance is non‑GAAP diluted EPS of $4.10–$4.15 (up 5%–8%, reflecting ~ $0.05 of Viewpoint dilution), a full‑year tariff headwind of ~$15M (≈$0.19/sh vs $9M/ $0.12 realized in late‑2025), and the company will reassess tariff/refund assumptions after Q2. For Q2 specifically Merit expects revenue of $400M–$410M (GAAP +5%–7%, ~4%–7% cc), inorganic Q2 revenue of ~$4.0–4.5M (organic cc growth ~3%–5%), non‑GAAP operating margin of ~18.7%–20.4% (vs 21.2% LY) and non‑GAAP EPS of $0.90–$1.00 (vs $1.10 LY); management reiterated CGI targets and plans to update guidance when reporting Q2 results.

Revenue Beat and Growth

Total revenue $381.9M, up 7% year-over-year (GAAP) and up 5% on a constant currency basis; results exceeded the high end of prior expectations.

Organic Growth

Organic constant currency growth 2.7% in Q1; excluding divested DualCap revenue, organic constant currency growth was 3.7%.

Profitability Improvement

Non-GAAP operating margin improved to 19.7%, up 47 basis points year-over-year (highest first-quarter operating margin in company history); operating income increased ~10% to $75.3M.

Earnings and Cash Generation

Non-GAAP EPS grew ~9% to $0.94 (Q1) and net income was $56.7M (vs $52.9M prior year); free cash flow $24.7M, up 26% year-over-year.

Strategic M&A and Product Adds

Acquired Viewpoint Medical for $140M (Apr 1) to expand oncology/localization portfolio (OneMark); BioLife and C2 Cryo Balloon acquisitions contributed and exceeded expectations.

Positive Guidance Update

FY2026 guidance updated to GAAP net revenue growth 6.3%–7.8% (constant currency 5.6%–7.0%); non-GAAP diluted EPS guidance $4.10–$4.15, up 5%–8% (includes $0.05 dilution from Viewpoint).

New Reporting and Platform Strategy

Introduced revenue presentation by 'foundational' (~2/3 of 2025 revenue; 6% 3-year CAGR) and 'therapeutic' (~1/3; 11% organic 3-year CAGR) and formalized eight platform operating model to align commercial/R&D.

Merit Medical Systems (MMSI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MMSI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 29, 2026	2026 (Q2)	0.96 / -	1.01	―	―	―
Apr 30, 2026	2026 (Q1)	0.83 / 0.94	0.86	9.30% (+0.08)
Feb 24, 2026	2025 (Q4)	0.95 / 1.04	0.93	11.83% (+0.11)
Oct 30, 2025	2025 (Q3)	0.83 / 0.92	0.86	6.98% (+0.06)
Jul 30, 2025	2025 (Q2)	0.85 / 1.01	0.92	9.78% (+0.09)
Apr 24, 2025	2025 (Q1)	0.75 / 0.86	0.77	11.69% (+0.09)
Feb 25, 2025	2024 (Q4)	0.83 / 0.93	0.81	14.81% (+0.12)
Oct 30, 2024	2024 (Q3)	0.80 / 0.86	0.75	14.67% (+0.11)
Aug 01, 2024	2024 (Q2)	0.87 / 0.92	0.81	13.58% (+0.11)
Apr 30, 2024	2024 (Q1)	0.71 / 0.77	0.64	20.31% (+0.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MMSI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 30, 2026	$68.18	$62.01	-9.05%
Feb 24, 2026	$82.43	$79.23	-3.88%
Oct 30, 2025	$83.04	$87.54	+5.42%
Jul 30, 2025	$82.96	$84.86	+2.29%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Merit Medical (MMSI) report earnings?

Merit Medical (MMSI) is schdueled to report earning on Jul 29, 2026, After Close (Confirmed).

What is Merit Medical (MMSI) earnings time?

Merit Medical (MMSI) earnings time is at Jul 29, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MMSI EPS forecast?

MMSI EPS forecast for the fiscal quarter 2026 (Q2) is 0.96.